Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction
Phase of Trial: Phase III
Latest Information Update: 14 Jul 2017
Price : $35 *
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms PANTASTIC
- 31 Aug 2018 Biomarkers information updated
- 11 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 05 Mar 2015 Planned End Date changed from 1 Dec 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.